Skip to Content
Merck
  • Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.

Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder.

European archives of psychiatry and clinical neuroscience (2011-11-08)
Alberto Chiesa, Concetta Crisafulli, Stefano Porcelli, Changsu Han, Ashwin A Patkar, Soo-Jung Lee, Moon Ho Park, Tae-Youn Jun, Alessandro Serretti, Chi-Un Pae
ABSTRACT

The present study is aimed to exploring whether some single nucleotide polymorphisms (SNPs) within GRIA1, GRIA2 and GRIA4 could be associated with major depressive disorder (MDD) and whether they could predict clinical outcomes in Korean in-patients, respectively, treated with antidepressants. One hundred forty-five (145) patients with MDD and 170 healthy controls were genotyped for 17 SNPs within GRIA1, GRIA2 and GRIA4. Baseline and final clinical measures, including the Montgomery-Asberg Depression Rating Scale (MADRS) for patients with MDD, were recorded. No association was observed between alleles, genotypes and haplotypes under investigation and clinical and demographical variables. As a secondary finding, a marginal association was observed between rs4302506 and rs4403097 alleles within GRIA2 and age of onset in patients with MDD. Our findings provide evidence for a possible association between rs4302506 and rs4403097 SNPs and age of onset in patients with MDD. However, taking into account that the several limitations of our study including the moderately small sample size of our study, our findings should be considered with caution and further research is needed to draw more definitive conclusions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-GRIA2 (AB2) antibody produced in rabbit, IgG fraction of antiserum
Sigma-Aldrich
Anti-GRIA2 (AB1) antibody produced in rabbit, IgG fraction of antiserum